Reports: Tuberculosis R&D funding still falling short
Global funding has reached an all-time high but falls far short of what's needed to eliminate TB.
Typhoid vaccine shows protection in phase 3 trial
The efficacy of the conjugate vaccine was thus 82%, and it had a good safety profile.
Trial finds biomarkers fail to curtail antibiotics in severe pneumonia
Rapid, biomarker-guided tests did not help cut antibiotic use in ICU patients.